What has been studied
Trials and clinical guidance have evaluated standardized THC:CBD oromucosal spray for spasticity associated with multiple sclerosis. These results should not be transferred automatically to smoked cannabis, CBD-only products, or unstandardized extracts.
Spasticity measures include patient-reported symptoms, clinician ratings, mobility, pain, daily function, and quality of life. Improvement on one measure does not guarantee improvement on all of them.
A conditional place in care
NICE guidance allows a time-limited trial of THC:CBD spray for adults with moderate to severe multiple-sclerosis spasticity when other pharmacological treatments have not worked, with specialist initiation and continuation tied to response. The guidance also describes limitations in evidence quality and cost effectiveness.
Other jurisdictions authorize different products and use different thresholds. Availability is a legal and regulatory question separate from clinical evidence.
Why supervision matters
Spasticity sometimes supports posture or transfers, so reducing it can have unintended functional effects. A specialist can set treatment goals, measure response, review adverse effects and interactions, and decide whether continued treatment is justified.